These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 33290872)

  • 1. MicroRNA-638 induces apoptosis and autophagy in human liver cancer cells by targeting enhancer of zeste homolog 2 (EZH2).
    Zhang H; Liang H; Wu S; Zhang Y; Yu Z
    Environ Toxicol Pharmacol; 2021 Feb; 82():103559. PubMed ID: 33290872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.
    Xu L; Beckebaum S; Iacob S; Wu G; Kaiser GM; Radtke A; Liu C; Kabar I; Schmidt HH; Zhang X; Lu M; Cicinnati VR
    J Hepatol; 2014 Mar; 60(3):590-8. PubMed ID: 24211739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiR-124 induces autophagy-related cell death in cholangiocarcinoma cells through direct targeting of the EZH2-STAT3 signaling axis.
    Ma J; Weng L; Wang Z; Jia Y; Liu B; Wu S; Cao Y; Sun X; Yin X; Shang M; Mao A
    Exp Cell Res; 2018 May; 366(2):103-113. PubMed ID: 29530475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-101 regulates autophagy, proliferation and apoptosis via targeting EZH2 in laryngeal squamous cell carcinoma.
    Chen L; Jia J; Zang Y; Li J; Wan B
    Neoplasma; 2019 Jul; 66(4):507-515. PubMed ID: 30868890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiRNA-26a Contributes to the Acquisition of Malignant Behaviors of Doctaxel-Resistant Lung Adenocarcinoma Cells through Targeting EZH2.
    Chen J; Xu Y; Tao L; Pan Y; Zhang K; Wang R; Chen LB; Chu X
    Cell Physiol Biochem; 2017; 41(2):583-597. PubMed ID: 28214878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2.
    Zhang JG; Guo JF; Liu DL; Liu Q; Wang JJ
    J Thorac Oncol; 2011 Apr; 6(4):671-8. PubMed ID: 21270667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-101-3p induces autophagy in endometrial carcinoma cells by targeting EZH2.
    Wang C; Liu B
    Arch Gynecol Obstet; 2018 Jun; 297(6):1539-1548. PubMed ID: 29691644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiR-32 Inhibits Proliferation and Metastasis by Targeting EZH2 in Glioma.
    Zhang Y; Wang J; An W; Chen C; Wang W; Zhu C; Chen F; Chen H; Zheng W; Gong J
    Technol Cancer Res Treat; 2019; 18():1533033819854132. PubMed ID: 31138033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-144 Suppresses Prostate Cancer Growth and Metastasis by Targeting EZH2.
    Sun XB; Chen YW; Yao QS; Chen XH; He M; Chen CB; Yang Y; Gong XX; Huang L
    Technol Cancer Res Treat; 2021; 20():1533033821989817. PubMed ID: 33550923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-137 suppresses migration and invasion by targeting EZH2-STAT3 signaling in human hepatocellular carcinoma.
    Huang B; Huang M; Li Q
    Pathol Res Pract; 2018 Dec; 214(12):1980-1986. PubMed ID: 30274685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of EZH2 in aerobic glycolysis of prostate cancer through miR-181b/HK2 axis.
    Tao T; Chen M; Jiang R; Guan H; Huang Y; Su H; Hu Q; Han X; Xiao J
    Oncol Rep; 2017 Mar; 37(3):1430-1436. PubMed ID: 28184935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-31 triggers G
    Sun KK; Shen XJ; Yang D; Gan MQ; Liu G; Zhang YF; Hua P; Wang HD; Wu XY
    Arch Biochem Biophys; 2019 Mar; 663():269-275. PubMed ID: 30677405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancer of zeste homolog 2 participates in the process of atherosclerosis by modulating microRNA-139-5p methylation and signal transducer and activator of transcription 1 expression.
    Zheng X; Zhao X; Han Z; Chen K
    IUBMB Life; 2021 Jan; 73(1):238-251. PubMed ID: 33331071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-137 is negatively associated with clinical outcome and regulates tumor development through EZH2 in cervical cancer.
    Zhang H; Yan T; Liu Z; Wang J; Lu Y; Li D; Liang W
    J Cell Biochem; 2018 Jan; 119(1):938-947. PubMed ID: 28681918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased miR-124 contributes to the epithelial-mesenchymal transition phenotype formation of lung adenocarcinoma cells via targeting enhancer of zeste homolog 2.
    Wu J; Li L; Zhang Y; Zhu J
    Pathol Res Pract; 2020 Jun; 216(6):152976. PubMed ID: 32370988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential roles of EZH2, Bmi-1 and miR-203 in cell proliferation and invasion in hepatocellular carcinoma cell line Hep3B.
    Yang F; Lv LZ; Cai QC; Jiang Y
    World J Gastroenterol; 2015 Dec; 21(47):13268-76. PubMed ID: 26715809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of aberrantly activated HOTAIR/EZH2/miR-193a feedback loop in progression of prostate cancer.
    Ling Z; Wang X; Tao T; Zhang L; Guan H; You Z; Lu K; Zhang G; Chen S; Wu J; Qian J; Liu H; Xu B; Chen M
    J Exp Clin Cancer Res; 2017 Nov; 36(1):159. PubMed ID: 29141691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ANLN-induced EZH2 upregulation promotes pancreatic cancer progression by mediating miR-218-5p/LASP1 signaling axis.
    Wang A; Dai H; Gong Y; Zhang C; Shu J; Luo Y; Jiang Y; Liu W; Bie P
    J Exp Clin Cancer Res; 2019 Aug; 38(1):347. PubMed ID: 31395079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EZH2-mediated Epigenetic Silencing of miR-29/miR-30 targets LOXL4 and contributes to Tumorigenesis, Metastasis, and Immune Microenvironment Remodeling in Breast Cancer.
    Yin H; Wang Y; Wu Y; Zhang X; Zhang X; Liu J; Wang T; Fan J; Sun J; Yang A; Zhang R
    Theranostics; 2020; 10(19):8494-8512. PubMed ID: 32754259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EZH2 promotes hepatocellular carcinoma progression through modulating miR-22/galectin-9 axis.
    Chen S; Pu J; Bai J; Yin Y; Wu K; Wang J; Shuai X; Gao J; Tao K; Wang G; Li H
    J Exp Clin Cancer Res; 2018 Jan; 37(1):3. PubMed ID: 29316949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.